SCHEMBL14101238

SCHEMBL14101238

CCOC(=O)c1nc(-c2ccc(C)cc2)c(-c2ccc(C)cc2)nc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 3/20 0.56
GABRA2 P47869 1/20 0.50
GABRB2 P47870 1/20 0.50
TRPM8 Q7Z2W7 1/20 0.48
CYP19A1 P11511 1/20 0.47
CYP1A2 P05177 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
ADORA3 P0DMS8 2/20 0.46
ALDH1A1 P00352 4/20 0.46
MAPT P10636 3/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
HTT P42858 1/20 0.44
MEN1 O00255 1/20 0.44
PKM P14618 1/20 0.44
KMT2A Q03164 1/20 0.44
SIRT2 Q8IXJ6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4680307 0.93 TARBP2 (0.54) TARBP2GABRA2GABRB2TRPM8CYP19A1
SCHEMBL4679991 0.93 TARBP2 (0.54) TARBP2GABRA2GABRB2TRPM8CYP19A1
SCHEMBL4680961 0.88 TARBP2 (0.58) TARBP2GABRA2GABRB2TRPM8CYP19A1
SCHEMBL5804495 0.88 TARBP2 (0.44) TARBP2GABRA2GABRB2CYP1A2NPC1
SCHEMBL4677848 0.85 ALDH1A1 (0.57) RAB9AALDH1A1MAPTKDM4EGAA
SCHEMBL4681325 0.82 TARBP2 (0.53) TARBP2GABRA2GABRB2TRPM8CYP19A1
SCHEMBL4679751 0.81 ALDH1A1 (0.44) TARBP2RAB9AALDH1A1MAPTKDM4E
SCHEMBL27634864 0.81 TARBP2 (0.50) TARBP2GABRA2GABRB2TRPM8CYP19A1
SCHEMBL27656015 0.81 TARBP2 (0.50) TARBP2GABRA2GABRB2TRPM8CYP19A1
SCHEMBL5752570 0.80 TARBP2 (0.52) TARBP2GABRA2GABRB2TRPM8CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1638953-B1 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS ASTRAZENECA AB (SE) 2008-08-27 EP disclosed
US-20070093484-A1 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators ASTRAZENECA AB (SE) 2007-04-26 US disclosed
US-20070093484-A1 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators ASTRAZENECA AB (SE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093484-A1 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators CNR2, CNR1, FAAH TARBP2 3058/4885GABRA2 76/4885GABRB2 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.